[HTML][HTML] Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

K Van Baelen, T Geukens, M Maetens… - Annals of …, 2022 - Elsevier
Background Invasive lobular breast cancer (ILC) is the second most common type of breast
cancer after invasive breast cancer of no special type (NST), representing up to 15% of all …

Lobular breast cancer: Clinical, molecular and morphological characteristics

M Christgen, D Steinemann, E Kühnle, F Länger… - … -Research and Practice, 2016 - Elsevier
Infiltrating lobular breast cancer (ILBC) is the most common special breast cancer subtype.
This review provides a comprehensive description of ILBC characteristics, including …

Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in …

MS Moran, SJ Schnitt, AE Giuliano, JR Harris… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Controversy exists regarding the optimal margin width in breast-conserving surgery
for invasive breast cancer. Methods A multidisciplinary consensus panel used a meta …

Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study

LE Lamberts, M Koch, JS de Jong, ALL Adams… - Clinical Cancer …, 2017 - AACR
Purpose: To provide proof of principle of safety, breast tumor–specific uptake, and positive
tumor margin assessment of the systemically administered near-infrared fluorescent tracer …

Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma

Y Adachi, J Ishiguro, H Kotani, T Hisada, M Ichikawa… - BMC cancer, 2016 - Springer
Background The pathological and clinical features of invasive lobular carcinoma (ILC) differ
from those of invasive ductal carcinoma (IDC). Several studies have indicated that patients …

Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neo-adjuvant chemotherapy combined with …

Y Kubota, Q Han, N Masaki, C Hozumi… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Invasive lobular carcinoma (ILC) of the breast has a low complete-
response rate in the neoadjuvant-chemotherapy setting. The addiction to methionine is a …

Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy

J Luveta, RM Parks, DM Heery, KL Cheung… - Oncology and …, 2020 - Springer
Abstract Invasive lobular carcinoma comprises 10–15% of all breast cancers and is
increasingly recognised as a distinct and understudied disease compared with the …

Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?

J Yu, EM da Silva, HS La, BZ Clark, JL Fine… - NPJ Breast …, 2023 - nature.com
This study describes “lobular-like invasive mammary carcinomas”(LLIMCas), a group of low-
to intermediate-grade invasive mammary carcinomas with discohesive, diffusely infiltrative …

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

S Loibl, C Volz, C Mau, JU Blohmer, SD Costa… - Breast cancer research …, 2014 - Springer
Invasive lobular carcinomas (ILC) show better clinical behaviour compared with other
histological types, but significantly lower pathological complete response (pCR) rates after …

Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: a propensity score matching study based on SEER …

C Yang, C Lei, Y Zhang, J Zhang, F Ji, W Pan… - Frontiers in …, 2020 - frontiersin.org
Objective Invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) account for
most breast cancers. However, the overall survival (OS) differences between ILC and IDC …